3.3. Infant Health
infectious diseases, upper respiratory disease, infectious disease, allergic disease, allergic diseases
INFECTIOUS DISEASES, INFECTIOUS DISEASE, ADVERSE EVENT, ATOPIC DERMATITIS
Infants who experienced at least one infectious or allergic disease during the study were reported as having an adverse event (AE), and the results are summarized in A total of 12 infants had infectious diseases during the trial, including 5 in the AP-32 group, and 2 each in the CP-9 group and placebo group. The results also revealed that a common infectious disease was upper respiratory disease, with one infant in each group affected. Three infants in each of the three treatment groups had allergic diseases. The most frequently reported allergic disease was atopic dermatitis, which was reported in 4 infants—1 each in the AP-32 and placebo groups and 2 in the CP-9 group. None of these AEs were considered study product-related. Notably, 86% of infants had no AEs during the study. The frequency of AEs occurred randomly among the three treatment groups, and there was no causal relationship between AEs and study products. Most infants showed no changes in the symptoms of digestive tolerance during the study period (